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OutcomeAbstract Context: Treatment of multidrug resistant tuberculosis (MDR-TB) is challenging. In
India, standard treatment regimen is established by Revised National Tuberculosis Control
Programme (RNTCP). Adequate follow-up of patients during the treatment period is a challenging
task under programmatic conditions. We did a retrospective analysis of patients enrolled and
treated under the national programme to study the outcome.
Aims: To study the treatment outcome of MDR-TB and the factors affecting it.
Settings and design: Retrospective analysis of 69 patients treated with standard regimen for
MDR-TB, as per RNTCP guidelines.
Methods and material: Retrospective analysis of 69 MDR-TB patients for the clinical and demo-
graphic profile. Treatment outcome is defined as cure rate, default rate, death rate and failure. The
factors affecting this outcome are also studied.
Results: Sputum culture conversion rate was 33.9% and 62.5% at 3rd and 6th month of treat-
ment respectively. Cure rate was 47.8%, death rate 27.5%, default rate 14.5% and failure 7.3%.
Conclusions: Themajor hindrance in achieving a good cure-rate was a high death rate and default.
Early diagnosis ofMDR-TB and adequate clinical monitoring during treatment is essential. Identify-
ing adverse drug reactions, other co morbidities and their optimal management is the key to success.
 2015 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Multi drug resistant tuberculosis (defined as resistance to at
least Rifampicin and Isoniazid) is a worldwide public healthproblem. As per recent global tuberculosis report of WHO,
5% of TB cases are estimated to have MDR-TB globally.
3.5% incidence of MDR-TB is reported among new cases.
The proportion is higher among previously treated cases,
about 20.5%. As per the data provided by national TB pro-
grams in 2013, an estimated 300,000 cases of MDR-TB are
present. More than half of these cases were in India, China
and the Russian federation [1].
Table 1 Demographic and clinical profile.
Patient characteristics
Age, yrs <30 30 43.50%
30–50 30 43.50%
>50 9 13.00%
Sex Male 46 66.67%
Female 23 33.33%
Body weight (kg) <30 2 2.90%
>30 67 97.10%
Residence Urban 39 56.52%
Rural 30 43.48%
Alcoholic 12 17.39%
Diabetes mellitus 8 11.59%
HIV positive 3 4.40%
Sputum bacterial load 3+ 19 27.54%
2+ 13 18.84%
1+ 37 53.62%
Disease extent (chest X-ray) Minimal 19 27.54%
Extensive 16 72.46%
B/L 44 63.77%
Cavitary 34 49.28%
Resistance pattern RH only 13 18.84%
RHE 11 15.94%
RHS 20 28.98%
HRES 25 36.23%
Previous treatment Cat I failure 14 20.29%
Cat II failure 55 79.71%
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tant TB in 1996. Programmised management for drug resistant
tuberculosis (PMDT) services in India was initiated from
August 2007. A standard category IV regimen for MDR-TB
treatment has been approved in India. It is implemented under
Revised National Tuberculosis Control Programme
(RNTCP)-National DOTS plus committee [2]. Globally, only
48% of MDR-TB cases detected in 2011 were successfully trea-
ted. 16% died, 24% did not have their treatment documented
or treatment interrupted and 12% were not cured despite
proper treatment [1]. So, any effort made to determine the
treatment outcome helps us to evaluate the programme, its
efficacy and identifying the constraints.
Materials and methods
A retrospective cohort study of MDR-TB cases enrolled for
treatment in 2011–2012 was done at SDSTRC and Rajiv
Gandhi Institute of Chest Diseases (RGICD), a tertiary chest
institute in Bangalore, India. Data were obtained from case
sheets, registers and treatment cards of patients from August
2011 to August 2014.
Study population – All MDR-TB cases confirmed by
RNTCP accredited laboratory and initiated with therapy from
August 2011 to June 2012 as per PMDT guidelines. Patients
belonged to various districts of Karnataka state.
All patients were hospitalised for pre-treatment
investigations and treatment initiation. Patients were started
on standardised Cat-IV regimen which includes Kanamycin,
Levofloxacin, Ethionamide, Pyrazinamide, Ethambutol,
Cycloseriene for 6–9 months and Levofloxacin, Ethionamide,
Ethambutol and Cycloseriene for 18 months. PAS was used as
a substitute drug in the case of major adverse effect or initial
resistance to any of the second line drugs. Patients were moni-
tored for tolerance and adverse drug reactions. After 10–30 days
of hospitalisation, patients continued community based treat-
ment at peripheral centres. Follow up sputum smears and cul-
ture were done as per guidelines. For follow up examination
the sputum specimens were collected and examined by smear
and culture at least 30 days apart from the 3rd to 7th month
of treatment (i.e. at the end of the months 3, 4, 5, 6 and 7) and
at 3-monthly intervals from the 9th month onward till the com-
pletion of treatment (i.e. at the end of themonths 9, 12, 15, 18, 21
and 24). Patients will be considered culture converted after hav-
ing two consecutive negative cultures taken at least one month
apart. Time to culture conversion is calculated as the interval
between the date of MDR-TB treatment initiation and the date
of the first of these two negative consecutive cultures. Patients
were referred to RGICD for management of any adverse drug
reactions and for declaration of treatment outcome. Data were
compiled and analysed for various demographic, clinico-
radiological profile and treatment outcome.
Outcome definitions:
 Cure: A patient who has completed treatment and has been
consistently culture negative (with at least 5 consecutive
negative results in the last 12–15 months). If one follow-
up positive culture is reported during the last three quarters,
patient will still be considered cured provided this positive
culture is followed by at least 3 consecutive negative
cultures, taken at least 30 days apart, provided that there
is clinical evidence of improvement. Treatment completed: A patient who has completed
treatment according to guidelines but does not meet the
definition for cure or treatment failure due to lack of bacte-
riological results.
 Treatment failure: Treatment will be considered to have
failed if two or more of the five cultures recorded in the final
12–15 months are positive, or if any of the final three
cultures are positive.
 Death: A patient who dies for any reason during the course
of MDR-TB treatment.
 Treatment default: A patient whose treatment was inter-
rupted for two or more consecutive months for any reasons.
 Transfer out: A patient who has been transferred to another
reporting unit (DR-TB Centre in this case) and for whom
the treatment outcome is not known. Till the time the
PMDT services are available across the country, the
MDR-TB patients can be transferred out only to those dis-
tricts, within or outside the state, where these services are
available. If a patient moves from one district to another,
both of which are covered by the same DR-TB Centre,
transfer out will not be required.
Results
The study included 69 proved MDR-TB patients enrolled for
treatment. Demographic, clinico-radiological and resistance
profile of patients are described in Table 1.
Of the 69 patients 46 were male (66.7%) and 23 were
females (33.3%). Mean age of the patients was 35.8 years
(11–65 years) and mean body weight was 46.5 kg (19–72 kgs).
Both urban and rural populations were affected almost
equally. 12 patients (17.4%) were alcoholic. 55 patients were
Figure 2 Conversion rate at 3, 3–6 and 6–12 month interval.
Management of multidrug resistant tuberculosis 449re-treatment (Cat-II) failure and 14 patients (20.3%) were Cat-
I failure. 3 patients had a history of treatment with 2 or more
second line drugs for more than one month.
72.5% had radiological evidence of extensive disease
(defined as presence of cavities and/or moderately dense infil-
trates involving more than one lobe); 63.8% had bilateral dis-
ease and 19.3% had cavitary disease. 37 patients (53.6%) had
initial sputum smear grade 1+/less and only 27.5% had 3+
grade. Resistance pattern to first line drugs varied. 25 patients
(36.2%) were resistant to SHRE, 20 patients (29%) were HRS
resistant. 11 patients (16%) were resistant to HRE and 13
patients (18.8%) were HR resistant. Concomitant medical dis-
ease was present in 20 (29%) cases. 8 (11.6%) were diabetic
and 3 (4.4%) were HIV positive. All HIV positive cases were
already on anti-retroviral treatment.
Of the total 69 patients 49 strictly adhered to treatment but
20 (29%) were irregular. 13 patients had not completed treat-
ment of even 3 months and so follow up sputum results were
available for 56 patients. Among these 56 patients, 48
(82.14%) had sputum culture conversion between 3 and
12 months. Culture conversion rate was 33.9% (19/56) and
62.5% (35/56) at 3 months and 6 months respectively (Fig. 2).
At the end of the treatment period, 33 patients (47.8%)
were declared cured, 19 died (27.5%), 10 defaulted (14.5%),
5 were failures (7.3%) and 2 transferred out (Fig. 1). Of the
33 cured patients, 14 (42.4%) had sputum conversion by
3 months and 26 (78.8%) by 6 months. Only 7 converted
between 6 and 12 months of treatment.
Failures
Out of 5 cases declared as failures, 2 had a history of second
line drugs for 6–12 months prior to starting of Cat-IV treat-
ment. 2 cases were confirmed to be XDR-TB (Kanamycin
and Ofloxacin resistant). 1 had only Ofloxacin resistance.
Expired cases
Out of 19 patients who died during the treatment period only 3
were females. 16 cases had extensive disease on chest X-ray. 10
patients died before 3 months of treatment and no follow up cul-
ture was available. 5 (26.3%) patients had sputum conversion
before death. 6 patientswere not adherent to treatment. 6 patients
died due to nonTBcauses like hepatic encephalopathy secondary
to cirrhosis, corpulmonale,malignancy. 1 wasHIVpositive and 1
was diabetic. 3 patients committed suicide; 1within 2 months and
2 after 10–14 months of treatment. 2 hadmajor adverse reactions
like hepatotoxicity and hypothyroidism.Figure 1 Treatment outcome.Default cases
Out of the 10 defaulters, 8 were males, 5 alcoholics. 6 patients
completed 12 months of treatment and 5 (50%) had sputum
conversion prior to default. 6 (60%) patients cited adverse
drug reaction as the cause of default (5-severe Gastritis and
intolerance, 1-Ototoxicity) 2 had associated diabetes mellitus
and 1 was migratory.
Adverse drug reactions (Table 2)
60.9% of 69 MDR-TB patients had adverse drug reactions of
varying severity. 32 (46.4%) had minor reactions, requiring
no/ temporary modification of treatment regimen. Most com-
mon (21.7%) were related to gastrointestinal systems like nau-
sea, vomiting and abdominal discomfort. 10 (14.5%) patients
complained of severe adverse reaction requiring treatment
modification. These included severe arthralgia (2 patients),
otovestibular toxicity (3) nephrotoxicity (1) mental distur-
bances (3) and hypothyroidism (1) (see Table 2).
Discussion
Our study involved outcome analysis of MDR-TB patients
managed with standardised a treatment regimen of 24 months
under programmatic conditions of RNTCP.
Sputum culture conversion is the first indicator of the
response to treatment and early conversion is definitely desir-
able. In our study 82.14% achieved sputum culture conversionTable 2 Adverse drug reactions.
ADR n (%)
Gastrointestinal 15 (21.7)
Otovestibular toxicity 5 (7.2)
Arthralgia 6 (8.7)
Jaundice 2 (2.9)
Cutaneous 4 (5.8)
Swelling at injection site 4 (5.8)
Nephrotoxicity 1 (1.5)
Hypothyroidism 2 (2.9)
Behavioural changes/depression/psychosis 3 (4.3)
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was only 33.9% in contrast to 82% reported from TRC
Chennai [3] and LRS Delhi [4], 57% at the Ahmedabad centre
[5]. At the time this cohort of patients was under treatment,
there was only one reference laboratory catering to entire state
MDR-TB patients. Delay in sending follow up samples,
contamination being reported in culture reports can be a
reason to some extent.
Default rate (14.5%) was low as observed in studies done in
Chennai [3] (13.16%), Egypt [6] (14%) and Bangladesh [7]
(12%) as compared to few other studies [4,5,8] reporting a high
default rate of 18–24%. Alcohol consumption, migration and
adverse drug reactions were found to be main causes for
default in our study.
Our study had a failure rate of 7.3%, similar to studies
from Delhi [4], Bangladesh [7] and Egypt [6]. But studies done
in Ahmedabad [5] and Chennai [3] reported a failure rate of
13–13.2% respectively.
A systematic review and meta- analysis of treatment
outcome of MDR-TB reported a cure rate of 62% [9]. A good
cure rate was also reported from other studies within and out-
side India using standardised treatment regimen [3,4,6,7].
However in our study we observed a cure rate of 47.8% only,
which is comparable to a low cure rate observed in a recent
studies in Ahmedabad [5] which reported a 39.13% cure rate
and also 48% from a study in Peru [10].
Relatively poor cure rate in our study was observed mainly
due to the high death rate (27.5%). 6 (31.6%) patients who
died had non TB causes like major co morbidities. However
outcome was equally good (62.5% cure rate) in MDR-TB
patients associated with diabetes mellitus. So, diabetes mellitus
was not influencing treatment outcome. 10 patients died even
before completing 3 months of treatment. Delay in diagnosing
and initiating treatment could be a cause. Extensive disease
and severe adverse drug reactions were seen in others. Unfor-
tunately 3 (15.8%) patients committed suicide during treat-
ment. Though social and family problems were quoted,
disease and Cycloseriene induced adjustment disorders,
depression and suicidal tendencies cannot be ruled out. Our
cohort contained MDR-TB patients from all districts of Kar-
nataka, who continued treatment from peripheral facilities
after treatment initiation at our institute. Clinical monitoring
through monthly follow up, as desirable was a non complaint
by the patients. So major adverse reactions could have been
ignored/missed at peripheral health facilities.
Only 36 patients (52.2%) completed 24–27 months of treat-
ment. Considering this 91.66% of those who completed the
treatment were declared cured. Even, 26% of patients who
died and 50% of defaulters had sputum conversion prior to
the incident. This indicates the good efficacy of the standard
treatment regimen. But, the major challenge is to keep patients
adhered to treatment and preventing default. Adequate follow
up, early identification and management of adverse drug reac-
tions are the key to favourable treatment outcome. Providing
good laboratory backup is a good aid for follow up. Major
behavioural disturbance and mental illness were caused possi-
bly due to Cycloseriene; delay in identifying the same under
programmatic conditions leading to casualty draws attention.
A prospective study on the same is needed so as to think about
substituting Cycloseriene with PAS in the regimen.Conclusion
Treatment of MDR-TB is definitely challenging. Standardised
treatment regimen is effective enough. Various treatment fac-
tors (long duration, adverse drug reactions) patient factors
(migration, extensive disease, non adherence, co morbidities)
and programmatic factors (lack of manpower, inadequate
laboratory facilities) are a major hindrance to the success.
Although many adverse drug reactions are reported, only
few of them are a limiting factor for treatment. Early diagnosis
of MDR-TB, strict follow-up of patients, adequate manage-
ment of other co morbidities, identifying major adverse drug
reactions and their early effective management increases the
cure rate.
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